Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Other Non-Current Assets (2019 - 2025)

aTYR PHARMA's Other Non-Current Assets history spans 7 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 24.26% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $2.2 million, down 24.26%, while the annual FY2025 figure was $2.2 million, 24.26% down from the prior year.
  • Other Non-Current Assets reached $2.2 million in Q4 2025 per ATYR's latest filing, up from $149000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $3.5 million in Q4 2023 to a low of $66000.0 in Q2 2025.
  • Average Other Non-Current Assets over 5 years is $2.1 million, with a median of $2.6 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: soared 1317.09% in 2022, then crashed 97.72% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $158000.0 in 2021, then skyrocketed by 1903.16% to $3.2 million in 2022, then rose by 10.08% to $3.5 million in 2023, then dropped by 15.3% to $3.0 million in 2024, then decreased by 24.26% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Other Non-Current Assets are $2.2 million (Q4 2025), $149000.0 (Q3 2025), and $66000.0 (Q2 2025).